Big biotech, Big pharma, Partnering, Pharma

MedImmune partners with Joslin for diabetes

Posted on 12 March 2015

Tags: , ,

MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders.

MedImmune and Joslin researchers will work collaboratively on research projects to identify new drug candidates.

Three initial projects have been identified, focusing on several key areas including protecting and regenerating the insulin producing beta cells, increasing the caloric utilization of fat depots (“beiging” white fat or expanding brown fat), and replicating the beneficial effects of bariatric surgery pharmacologically.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

The collaboration is structured with the potential for more projects to be added as new compelling science is identified.

MedImmune will provide research funding to Joslin and bring drug development expertise and capabilities to complement Joslin’s early metabolic disease research competencies and clinical care infrastructure.

MedImmune has the option to license development and commercial rights to projects emerging from the collaboration.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply